Tenax Therapeutics (TENX) Cash from Operations (2016 - 2017)
Historic Cash from Operations for Tenax Therapeutics (TENX) over the last 8 years, with Q4 2017 value amounting to -$1.3 million.
- Tenax Therapeutics' Cash from Operations rose 5871.04% to -$1.3 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$12.1 million, marking a year-over-year increase of 2350.65%. This contributed to the annual value of -$14.8 million for FY2024, which is 15086.38% down from last year.
- According to the latest figures from Q4 2017, Tenax Therapeutics' Cash from Operations is -$1.3 million, which was up 5871.04% from -$1.2 million recorded in Q3 2017.
- Tenax Therapeutics' Cash from Operations' 5-year high stood at -$1.2 million during Q3 2017, with a 5-year trough of -$63.5 million in Q1 2014.
- In the last 5 years, Tenax Therapeutics' Cash from Operations had a median value of -$3.6 million in 2015 and averaged -$15.6 million.
- As far as peak fluctuations go, Tenax Therapeutics' Cash from Operations surged by 9520.96% in 2014, and later crashed by 9385.69% in 2015.
- Quarter analysis of 5 years shows Tenax Therapeutics' Cash from Operations stood at -$60.8 million in 2013, then surged by 95.21% to -$2.9 million in 2014, then crashed by 31.95% to -$3.8 million in 2015, then increased by 19.2% to -$3.1 million in 2016, then skyrocketed by 58.71% to -$1.3 million in 2017.
- Its last three reported values are -$1.3 million in Q4 2017, -$1.2 million for Q3 2017, and -$5.6 million during Q2 2017.